The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme
Open accessAbstract
Background: Overuse of short-acting β 2-agonists (SABA) may indicate poor asthma control and adverse health outcomes. Contemporary population-based data on use, risk factors and impact of SABA (over)use on asthma exacerbations and mortality are scarce, prompting initiation of the global SABINA (SABA use IN Asthma) programme. Methods: By linking data from Swedish national registries, asthma patients aged 12–45 years with two or more collections of drugs for obstructive lung disease during 2006–2014 were included. SABA overuse was defined as collection of more than two SABA canisters in a 1-year baseline period following inclusion. SABA use was grouped into 3–5, 6–10 and ≥11 canisters per baseline-year. Cox regression was used to examine associations between SABA use and exacerbation (hospitalisations and/or oral corticosteroid claims) and mortality. Results: The analysis included 365 324 asthma patients (mean age 27.6 years; 55% female); average follow-up was 85.4 months. 30% overused SABA, with 21% collecting 3–5 canisters per year, 7% collecting 6–10 canisters per year and 2% collecting ≥11 canisters per year. Increasing number of collected SABA canisters was associated with increased risk of exacerbation, as follows. 3–5 canisters: hazard ratio (HR) 1.26 (95% CI 1.24–1.28); 6–10 canisters: 1.44 (1.41–1.46); and ≥11 canisters: 1.77 (1.72–1.83), compared to two or fewer canisters per year. Higher SABA use was associated with incrementally increased mortality risk (2564 deaths observed), as follows. 3–5 canisters: HR 1.26 (95% CI 1.14–1.39); 6–10 canisters 1.67 (1.49–1.87); and ≥11 canisters: 2.35 (2.02–2.72) compared to two or fewer canisters per year. Conclusion: One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. These findings emphasise that monitoring of SABA usage should be key in improving asthma management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
The Use of β-Agonists and the Risk of Death and near Death from Asthma
Spitzer, W. O., Suissa, S., Ernst, P., Horwitz, R. I., Habbick, B., Cockcroft, D., Boivin, J.-F., McNutt, M., Buist, A. S., & Rebuck, A. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260801 · Cited by 1,224
Regular inhaled beta-agonist treatment in bronchial asthma
Sears, M. R., Taylor, D. R., Print, C. G., Lake, D. C., Li, Q., Flannery, E. M., Yates, D. M., Lucas, M. K., & Herbison, G. P. (1990) · The Lancet · doi:10.1016/0140-6736(90)93098-a · Cited by 1,065
Respiratory health and disease in Europe: the new European Lung White Book
Gibson, G. J., Loddenkemper, R., Lundbäck, B., & Sibille, Y. (2013) · European Respiratory Journal · doi:10.1183/09031936.00105513 · Cited by 444
The Charlson Comorbidity Index in Registry-based Research: Which Version to Use?
Lagergren, J., & Brusselaers, N. (2017) · Methods of Information in Medicine · doi:10.3414/me17-01-0051 · Cited by 337
Asthma outcomes: Exacerbations
Fuhlbrigge, A., Peden, D., Apter, A. J., Boushey, H. A., Camargo, C. A., Gern, J., Heymann, P. W., Martinez, F. D., Mauger, D., Teague, W. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.983 · Cited by 326
Wallerstedt, S. M., Wettermark, B., & Hoffmann, M. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12613 · Cited by 262
Cited by
Porsbjerg, C., Melén, E., Lehtimäki, L., & Shaw, D. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02125-0 · Cited by 575
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02730-2021 · Cited by 537
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2205pp · Cited by 512
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update
Levy, M. L., Bacharier, L. B., Bateman, E., Boulet, L.-P., Brightling, C., Buhl, R., Brusselle, G., Cruz, A. A., Drazen, J. M., Duijts, L., et al. (2023) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-023-00330-1 · Cited by 361
van de Hei, S. J., Poot, C. C., van den Berg, L. N., Meijer, E., van Boven, J. F. M., Flokstra-de Blok, B. M. J., Postma, M. J., Chavannes, N. H., & Kocks, J. W. H. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001400 · Cited by 22
Metadata
- Authors
- Nwaru, B. I., Ekström, M., Hasvold, P., Wiklund, F., Telg, G., & Janson, C.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-01-16
- Volume
- 55
- Issue
- 4
- Pages
- 1901872
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2999425512
- Cited by
- 460
- References
- 21
- FWCI
- 34.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. https://app.cochat.ai/papers/10.1183/13993003.01872-2019
- The paper
- Nwaru, B. I., Ekström, M., Hasvold, P., Wiklund, F., Telg, G., & Janson, C. (2020). Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. European Respiratory Journal. https://doi.org/10.1183/13993003.01872-2019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.